- Home
- PMAX vs OGEN Comparison
PMAX vs OGEN Comparison
Compare PMAX & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- OGEN
- Stock Information
- Founded
- PMAX 2019
- OGEN 1996
- Country
- PMAX Hong Kong
- OGEN United States
- Employees
- PMAX N/A
- OGEN N/A
- Industry
- PMAX
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- PMAX
- OGEN Health Care
- Exchange
- PMAX Nasdaq
- OGEN Nasdaq
- Market Cap
- PMAX 5.3M
- OGEN 5.4M
- IPO Year
- PMAX 2024
- OGEN N/A
- Fundamental
- Price
- PMAX $1.98
- OGEN $1.10
- Analyst Decision
- PMAX
- OGEN
- Analyst Count
- PMAX 0
- OGEN 0
- Target Price
- PMAX N/A
- OGEN N/A
- AVG Volume (30 Days)
- PMAX 40.7K
- OGEN 39.7K
- Earning Date
- PMAX 09-23-2025
- OGEN 11-07-2025
- Dividend Yield
- PMAX N/A
- OGEN N/A
- EPS Growth
- PMAX N/A
- OGEN N/A
- EPS
- PMAX N/A
- OGEN N/A
- Revenue
- PMAX $4,799,100.00
- OGEN N/A
- Revenue This Year
- PMAX N/A
- OGEN N/A
- Revenue Next Year
- PMAX N/A
- OGEN N/A
- P/E Ratio
- PMAX N/A
- OGEN N/A
- Revenue Growth
- PMAX N/A
- OGEN N/A
- 52 Week Low
- PMAX $1.83
- OGEN $1.01
- 52 Week High
- PMAX $27.44
- OGEN $18.90
- Technical
- Relative Strength Index (RSI)
- PMAX 41.87
- OGEN 36.27
- Support Level
- PMAX $2.42
- OGEN $1.06
- Resistance Level
- PMAX $2.36
- OGEN $1.22
- Average True Range (ATR)
- PMAX 0.17
- OGEN 0.06
- MACD
- PMAX -0.11
- OGEN -0.01
- Stochastic Oscillator
- PMAX 7.61
- OGEN 13.04
About PMAX Powell Max Limited
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.